Regulatory Measures Could Mitigate EU Coronavirus Risks
Medicines For Europe Sets Out Potential Solutions To COVID-19 Impact
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
You may also be interested in...
Stakeholders across the European medicines industry must co-ordinate to plan for increases in demand as the region continues to grapple with the coronavirus outbreak, off-patent industry association Medicines for Europe has insisted.
Immediate EU-wide measures are needed to ensure the supply of medicines, according to off-patent industry association Medicines for Europe, which has also called for clear regulatory guidance and scenario planning to address the challenges posed by the coronavirus outbreak.
European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.